US Patent

US11351133 — Effects of heparin on topical use of plasters containing a non-steroidal anti-inflammatory drug

Method of Use · Assigned to Altergon SA · Expires 2035-02-20 · 9y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of improving the release of non-steroidal anti-inflammatory drugs from a plaster or bandage using heparin or a heparinoid.

USPTO Abstract

The present invention provides for a method of improving the release of non-steroidal anti-inflammatory drugs (NSAIDs) from a plaster or bandage comprising an adhesive layer with a pharmaceutically acceptable NSAID together with heparin or a heparinoid. The invention also provides for methods of reducing muscle hyperalgesia in subjects without spontaneous pain.

Drugs covered by this patent

diclofenac-epolamine (DICLOFENAC EPOLAMINE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3393`	—	diclofenac-epolamine

Patent Metadata

Patent number: US11351133
Jurisdiction: US
Classification: Method of Use
Expires: 2035-02-20
Drug substance claim: No
Drug product claim: No
Assignee: Altergon SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.